Day: February 6, 2025

TYSONS CORNER, Va. and PETAH TIKVA, Israel, Feb. 06, 2025 (GLOBE NEWSWIRE) — Cellebrite (NASDAQ: CLBT), a global leader in premier Digital Investigative solutions for the public and private sectors, today announced the general availability of Generative Artificial Intelligence (GenAI) capabilities within Guardian, the Company’s SaaS-based evidence management solution. By incorporating GenAI into Guardian, public safety agencies benefit from AI-driven productivity. Users can now form a more complete picture by quickly summarizing and contextualizing vast amounts of data, such as hours of audio messages or lengthy text message strings. Keywords and thematic direction accelerate an agency’s mission and empowers investigators who are reading, analyzing and validating the data with more insight on where to look next, including:Chat...

FORT MILL, S.C., Feb. 06, 2025 (GLOBE NEWSWIRE) — Catheter Precision, Inc. (VTAK – NYSE/American), a US based medical device company focused on developing technologically advanced products for the cardiac electrophysiology market announced their attendance at the 13th International Symposium on Left Atrial Appendage (ISLAA). ISLAA will take place on February 7th and 8th, 2025 in Austin, Texas. The ISLAA meeting is a multi-specialty cardiovascular educational symposium on the frontier science of left atrial appendage (LAA). Over two days, course directors and leading physicians from The Kansas City Heart Rhythm Institute, Texas Cardiac Arrhythmia Institute, Los Robles Medical Center, Mayo Clinic and Mt. Sinai will manage the program and content. In addition, the ISLAA meeting provides a unique opportunity for hands-on demonstrations...

Texas-based Association contracts to make FOREWARN services available for its 4,000+ real estate professional members to promote proactive agent safety BOCA RATON, Fla., Feb. 06, 2025 (GLOBE NEWSWIRE) — FOREWARN, LLC, a red violet company (NASDAQ: RDVT) and the leading provider of real-time information solutions for real estate agents, today announced that Greater Fort Worth Association of REALTORS® (“GFWAR”) will offer FOREWARN® services to its 4,000+ members it serves throughout the Greater Fort Worth metropolitan area to promote proactive real estate agent safety. Available both online and through a mobile application, FOREWARN analyzes billions of data points and provides users with the ability to mitigate risks by verifying identity, searching for criminal histories, and validating information provided by potential clients...

VANCOUVER, Washington, Feb. 06, 2025 (GLOBE NEWSWIRE) — CytoDyn Inc. (OTCQB: CYDY) (“CytoDyn” or the “Company”), a biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, announced today positive results from its preclinical studies with SMC Laboratories (“SMC”). The three studies demonstrated statistically significant reversal of liver fibrosis with leronlimab monotherapy (compared to an isotype IgG4 control arm with p-values across all 3 studies < 0.01). The first two studies, completed in late 2024, evaluated leronlimab in the STAM™ model of metabolic dysfunction associated steatohepatitis (MASH) with fibrosis in mice who received a single dose of Streptozocin at birth and were then fed a high fat diet from weeks four to twelve. The...

SALT LAKE CITY, Feb. 06, 2025 (GLOBE NEWSWIRE) — Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic and genomic tumor testing and precision medicine, and INTERLINK Care Management, Inc. announced an agreement designed to enhance education and access to hereditary cancer testing for CancerCARE for Life members. The agreement enables more than one million individuals within CancerCARE’s network to assess their eligibility for the MyRisk test by taking the MyGeneHistory® quiz, a guideline-based online patient screening tool. If they meet criteria, they can be directed to a clinician who can order the MyRisk® with RiskScore® Hereditary Cancer Test on their behalf. Patients who take the MyRisk test can then review their results with a Myriad genetic counselor. “MyRisk’s clear, actionable results provide the foundation for personalized...

First Focal One® procedure utilizing Cortechs.ai’s advanced MRI-imaging technology, OnQ Prostate, successfully performed at the University of California, San Francisco Prostate Cancer Center OnQ Prostate’s Restriction Spectrum Imaging (RSI) technology improves lesion localization and targeting for urologists performing Focal One Robotic High Intensity Focused Ultrasound (HIFU) ablation Reflects EDAP’s continued commitment to innovation and further validates Focal One as the leading focal therapy platform controlled by urologists  San Diego, CA and Austin, Texas, February 6, 2025 – Cortechs.ai, an emerging leader in novel imaging solutions for prostate cancer care, and EDAP TMS SA (Nasdaq: EDAP), the global leader in robotic energy-based therapies, today announced the successful completion of the world’s first OnQ Prostate-assisted...

PARSIPPANY, N.J., Feb. 06, 2025 (GLOBE NEWSWIRE) — Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in the delivery of innovative, non-opioid pain therapies to transform the lives of patients, today announced the granting of inducement awards on February 4, 2025 to 15 new employees under Pacira’s Amended and Restated 2014 Inducement Plan (the “Inducement Plan”) as a material inducement to each employee’s entry into employment with the company. In accordance with Nasdaq Listing Rule 5635(c)(4), the awards were approved by the Compensation Committee of the Board of Directors (the “Committee”) without stockholder approval. In connection with Brendan Teehan’s appointment as Chief Commercial Officer, the Committee approved the grant of inducement awards to Mr. Teehan. Mr. Teehan’s inducement awards included (i) a non-qualified...